---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-409052"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2026-09-30T20:08:28+00:00"
generated_at: "2026-10-12T14:04:52.890174+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Benitec engages Ernst & Young as auditor for fiscal year ending June 30, 2027

## Summary
- EY completed its client acceptance process on September 28, 2026, and executed the engagement letter with Benitec on September 29, 2026.
- The EY engagement covers the fiscal year ending June 30, 2027; the approval was previously disclosed in a Form 8-K filed September 24, 2026.
- Filing is an Item 4.01 change-in-certifying-accountant notice; no resignation, disagreement, or restatement disclosure is provided.
- Signed by Chief Executive Officer Dr. Jerel A. Banks, dated September 30, 2026.

## SEC filing metadata
- accession: 0001193125-26-409052
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2026-09-30T20:08:28+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 4.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312526409052/0001193125-26-409052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312526409052/bntc-20260929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-409052
- JSON: https://secwatch.observer/filing/0001193125-26-409052.json
- Plain text: https://secwatch.observer/filing/0001193125-26-409052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.